Home > Clinical Protocols > Oncology


Breast Cancer: An Integrative Consultation

Beth DuPree, MD, FACS, ABIHM
It is estimated that 1 in 8 women in the United States will develop invasive (infiltrating) breast cancer at some point in her lifetime. Ductal carcinoma, which begins in the milk ducts, accounts for 80% of all invasive breast cancers, and lobular carcinoma, which begins in the lobules, accounts for 10%. Invasive breast cancers are further categorized into several molecular and genomic subtypes.

Local treatment options for breast cancer depend on the tumor size, nodes, metastasis (TNM), and molecular subtype. Systemic treatment options depend on a patient’s overall health status and lifestyle. Breast cancer surgeon, Dr. Beth DuPree, urges clinicians to address both local and systemic factors in a holistic approach to the evaluation and treatment of breast cancer. In this discussion, she explains the diagnostic flow, surgical options, factors influencing treatment, and the role that integrative practitioners can play in the evaluation and early phases of breast cancer treatment.


Cancer: Biomarker Guided Risk Reduction

Nalini Chilkov, LAc, OMD
Three adults out of every 1,000 will experience a diagnosis of cancer each year in the United States. There are 14 million cancer survivors in the United States today and 18 million predicted by 2022. Practitioners are routinely faced with patients at risk of cancer occurrence or recurrence, yet many have limited knowledge of how to approach risk reduction in these patients. In the following discussion, Dr. Nalini Chilkov educates practitioners on value of using biomarkers to both assess and manage cancer risk in the general practice setting. Selected biomarkers can guide the use of interventions aimed at altering the bioterrain in order to reduce the risk of cancer incidence and recurrence.

Read more >>>

Colon Cancer Prevention

CE Button

Credentialed Through 2020

Tina Kaczor, ND, FABNO
Colorectal cancer (CRC) is the 3rd most common cancer in men and women in the United States. The lifetime risk of developing colorectal cancer is 1 in 5. Although family history and age are strong predictors of CRC risk, it has been estimated that modifiable risk factors may account for a substantial number of all CRC cases.

Despite the strong association between some of the non-modifiable risk factors and CRC, it has been estimated that as many as 70% of CRC cases might be prevented by lifestyle modification. Modifiable risk factors are influenced by diet, lifestyle, and evidence-based nutritional interventions, and these interventions can have a profound effect on CRC risk. An integrative approach can address modifiable risk factors that contribute to both increased CRC risk and to the disease process itself.In this discussion, Tina Kaczor, ND, FABNO, explains the importance of identifying and addressing modifiable risk factors of CRC.


Contemplative Cancer Care

Matt Mumber, MD
According to estimates from the American Cancer Society, there will be more than 1.6 million new cases of cancer diagnosed in the United States in 2015. In addition, almost 15 million Americans alive today are cancer survivors. Cancer is a diagnosis that can create distress, depression, anxiety, and other psychological challenges for patients, family members, caregivers, and the community. Standard therapies focus on eradicating the physical disease through surgery, chemotherapy, and radiation, but there are no definitive guidelines to address the emotional and psychosocial aspects of this disease. Evidence-based psychosocial interventions and mindfulness-based therapies show promise in their potential to improve the quality of life for cancer patients and cancer survivors. In this discussion, Dr. Matt Mumber shares his unique perspective on the importance of what he calls “contemplative care” in cancer.


Prostate Cancer: Integrative Management of Early Stage Prostate Cancer

Geo Espinosa, N.D., L.Ac, C.N.S., RH (AHG)
It is estimated that 3 million men are living in the United States with prostate cancer today. More than 180,000 new diagnoses are expected in the United States in 2016, and 1 in 7 men will develop prostate cancer in their lifetime. The risk for prostate cancer increases with advanced age, family history of prostate cancer, or African American descent. Fortunately, survival rates are good, with less than 15% of men with prostate cancer dying from the disease. The majority of cases of prostate cancer are slow-growing and diagnosed at a localized stage. Patients who are considered to be at low-risk for developing more aggressive cancer can opt for active surveillance rather than surgery or radiation. Active surveillance is defined as a monitoring program in patients with localized prostate cancer, intended to detect cancer growth as early as possible and intervene if there is evidence of more aggressive growth. In the following discussion, Dr. Geo Espinosa, ND, explains how to determine when active surveillance is appropriate, how to monitor patients, when to refer for conventional care, and what integrative therapies can be implemented during active surveillance of localized prostate cancer.


Skin Cancer: An Integrative Approach

Michael Traub, ND
There are more new cases of skin cancer each year than new cases of breast, prostate, lung, and colon cancers combined. Basal cell carcinoma (BCC) is the least aggressive and the most common form of skin cancer, with 4 million cases per year in the United States. Squamous cell carcinoma (SCC) is the second most common, with 1 million cases per year. Melanoma is the most deadly of all skin cancers, has a lifetime risk of 1 in 39 for men and 1 in 58 for women in the United States. Michael Traub, ND, discusses integrative options for risk reduction and adjunctive care for both nonmelanoma and melanoma skin cancers.